Navigation Links
Predictors of cancer disease progression improve patient selection for metastasis-directed therapy
Date:12/11/2012

December 10, 2012, New York, NY Tumor metastasis, the ability of cancer cells to migrate from their tissue of origin and colonize elsewhere in the body, accounts for over 90% of cancer deaths. When patients die from cancer, it is usually caused by distant metastases established by malignant cells that split off from the primary cancer and began growing in new settings.

Scientists from the Ludwig Center at the University of Chicago hypothesized over 15 years ago that an intermediate state of tumor spread or metastasis exists between patients with extensive metastasis and patients whose disease stays confined to one local tumor with no spread. The scientists termed this intermediate state oligometastasis or metastasis limited in number and location. They then demonstrated that some patients with oligometastasis can be cured with therapies including surgery and radiotherapy that are directed locally at the metastasis.

In a paper published December 10 in PLOS ONE, the Ludwig investigators led by Dr. Ralph Weichselbaum in collaboration with Dr. Yves Lussier at the University of Illinois, took their research a step further. They analyzed patients with lung metastasis who underwent surgical resection with curative intent.

What they found was that some patients were cured, some developed rapid metastasis, and some developed metastasis at a very slow rate of progression. They then asked themselves what accounted for these radical differences in patient outcomes.

The answer: microRNAs or small molecules that suppress gene expression or protein synthesis. The investigators had pinpointed the culprit. They identified the microRNAs associated with oligometastatic progression and then found that these microRNAs differ from those associated with patients who developed widespread metastatic disease.

The microRNAs associated with oligometastasis have tumor suppressor characteristics that differ from microRNAs associated with patients who developed widespread metastatic disease. The results demonstrate a biological basis for oligometastasis and a potential for using microRNA expression to identify patients most likely to remain oligometastatic after metastasis-directed treatment.

"With these findings, we are now able to use microRNA expression to characterize oligometastasis and ultimately better select patients with tumor metastasis for curative interventions," said study author Ralph Weichselbaum, MD, director of the Ludwig Center for Metastasis Research at the University of Chicago. "Also understanding the molecular basis of tumor metastasis will allow for the targeting of specific biological processes to treat patients with more advanced tumor spread."


'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Related biology news :

1. Biologists engineer algae to make complex anti-cancer designer drug
2. Fred Hutchinson Cancer Research Center partners with GlaxoSmithKline to develop muscular dystrophy therapeutics
3. Stem cell research provides hope for infertile cancer survivors
4. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
5. Clinical trial tests rice bran to prevent cancer
6. Nanotechnology drug delivery shows promise for treatment of pediatric cancer
7. Predicting the age at menopause of women having suffered from childhood cancers
8. Research shows immune system response is detrimental to novel brain cancer therapy
9. University of Tennessee researchers find fungus has cancer-fighting power
10. Newly discovered effects of vitamin D on cancer
11. Fruit fly studies guide investigators to misregulated mechanism in human cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... ... , ... Intelligent Implant Systems announced today that the two-level components for the ... United States. These components expand the capabilities of the system and allow Revolution™ ... October of 2015, the company has seen significant sales growth in 1Q 2016, and ...
(Date:4/28/2016)... 28, 2016 Q BioMed ... Company,s CEO  was featured in an article he ... VCs Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... is an essential business journal for life ... biotechs to Big Pharmas. Their content is designed ...
(Date:4/28/2016)... ... April 28, 2016 , ... As part of an ... experts, and expanding its LATAM network and logistics capabilities. Enhancements have been ... their clinical trial projects. , The expansion will provide unmatched clinical trial logistics ...
(Date:4/27/2016)... ... April 27, 2016 , ... Shimadzu Scientific Instruments (SSI) ... 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to test ... Expo attendees can stop by booth 1021 to learn how Shimadzu’s instruments can ...
Breaking Biology Technology: